{
  "ticker": "VYNE",
  "company_name": "VYNE Therapeutics Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03836001",
      "title": "A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Epidermolysis Bullosa",
      "start_date": "2019-04-18",
      "completion_date": "2022-06-24",
      "enrollment": 0,
      "sponsor": "Stanford University"
    },
    {
      "nct_id": "NCT04052711",
      "title": "A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2016-09-08",
      "completion_date": "2016-12-19",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    },
    {
      "nct_id": "NCT01494285",
      "title": "Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Acne Vulgaris",
      "start_date": "2012-06",
      "completion_date": "2013-10",
      "enrollment": 0,
      "sponsor": "M. Arkin 1999 Ltd."
    },
    {
      "nct_id": "NCT02250859",
      "title": "A Pharmacokinetic Study of Minocycline in Male and Female Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Acne",
      "start_date": "2014-09",
      "completion_date": "2015-01",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    },
    {
      "nct_id": "NCT03282591",
      "title": "Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Refractory Chronic Cough",
      "start_date": "2017-10-03",
      "completion_date": "2018-09-06",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    },
    {
      "nct_id": "NCT04064125",
      "title": "Dermal Cumulative Irritant Patch Study",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2016-09-01",
      "completion_date": "2016-10-28",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    },
    {
      "nct_id": "NCT03271021",
      "title": "A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Acne Vulgaris",
      "start_date": "2017-07-17",
      "completion_date": "2018-09-04",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    },
    {
      "nct_id": "NCT02239731",
      "title": "Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Rash Due to Epidermal Growth Factor Receptor Inhibitors",
      "start_date": "2014-10",
      "completion_date": "2015-10",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    },
    {
      "nct_id": "NCT01171326",
      "title": "Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Impetigo",
      "start_date": "2010-08",
      "completion_date": "2012-04",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    },
    {
      "nct_id": "NCT04070742",
      "title": "Dermal Phototoxicity Study",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2016-08-17",
      "completion_date": "2016-10-01",
      "enrollment": 0,
      "sponsor": "Vyne Therapeutics Inc."
    }
  ],
  "summary": {
    "total_trials": 37,
    "by_phase": {
      "PHASE2": 19,
      "PHASE1": 6,
      "PHASE1, PHASE2": 2,
      "PHASE3": 9,
      "PHASE4": 1
    },
    "by_status": {
      "COMPLETED": 32,
      "ACTIVE_NOT_RECRUITING": 1,
      "TERMINATED": 4
    },
    "active_trials": 1,
    "completed_trials": 32,
    "conditions": [
      "Acne",
      "Acne Vulgaris",
      "Alcohol Dependence",
      "Atopic Dermatitis",
      "Chronic Pruritus",
      "Epidermolysis Bullosa",
      "Epidermolysis Bullosa, Pruritus",
      "Facial Papulopustular Rosacea",
      "Healthy",
      "Impetigo",
      "Non-segmental Vitiligo",
      "Papulopustular Rosacea",
      "Prurigo Nodularis",
      "Pruritus",
      "Pruritus, Atopic Dermatitis",
      "Pruritus, Burns",
      "Pruritus, Prurigo Nodularis",
      "Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis",
      "Pruritus, Psoriasis",
      "Rash Due to Epidermal Growth Factor Receptor Inhibitors",
      "Refractory Chronic Cough",
      "Rosacea",
      "Rosacea, Papulopustular Rosacea",
      "Scabies",
      "Urinary Incontinence, Overactive Bladder"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T13:12:18.111354",
    "search_query": "VYNE Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/search?term=VYNE+Therapeutics+Inc."
  }
}